Tryptamine Therapeutics Ltd. is gearing up to enter the clinic with lead compound TRP-8803, an intravenous-infused psilocybin therapy, in patients with binge eating disorder in conjunction with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback